CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 1885-A |

# Specialty Guideline Management Orkambi

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Orkambi | lumacaftor/ivacaftor |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indication1

Orkambi is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.

#### Limitations of Use

The efficacy and safety of Orkambi have not been established in patients with CF other than those homozygous for the F508del mutation.

All other indications are considered experimental/investigational and are not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review: For initial requests, genetic testing report confirming the presence of the appropriate CFTR gene mutation.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a pulmonologist.

## Coverage criteria

### Cystic Fibrosis1

Authorization of 12 months may be granted for treatment of cystic fibrosis when all of the following criteria are met:

* Genetic testing was conducted to detect a mutation in the CFTR gene.
* The member is homozygous for the F508del mutation (positive for the F508del mutation on both alleles) of the CFTR gene.
* The member is at least 1 year of age.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section who are experiencing benefit from therapy as evidenced by disease stability or disease improvement (e.g., improvement in FEV1 from baseline).

## Other

Orkambi will not be used in combination with another CFTR modulator for the treatment of cystic fibrosis (e.g., Alyftrek, Symdeko).

## Reference

1. Orkambi [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; December 2024.